Cancer-related inflammation
Open accessThe DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.
Abstract
The mediators and cellular effectors of inflammation are important constituents of the local environment of tumours. In some types of cancer, inflammatory conditions are present before a malignant change occurs. Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours. Regardless of its origin, 'smouldering' inflammation in the tumour microenvironment has many tumour-promoting effects. It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents. The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, cytokine production can be triggered by oncogenic transformation, metabolic alteration, cell death, hypoxia, and the use of anti-cancer drugs (10).”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30,31,32,33].”
From Picroside II as a Potential Anti-Inflammatory Agent (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746 · cited 1×
“jpg" NDATA ITEM> ]> Links between cancer and inflammation were first made in the nineteenth century, on the basis of observations that tumours often arose at sites of chronic inflammation and that inflammatory cells were present in biopsied samples from tumour”
Self-citationMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“TAMs and related cell types in mouse and human tumours generally have an M2 phenotype, which is oriented towards promoting tumour growth, remodelling tissues, promoting angiogenesis and suppressing adaptive immunity&hairsp”
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“This type of response might also contribute to successful chemotherapy or radiotherapy, according to recent data obtained by Lionel Apetoh and colleague”
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032 · cited 1×
“Cancer-related inflammation and adaptive immunity There is strong evidence from genetic studies of mouse models that cells of the adaptive immune system carry out surveillance and can eliminate nascent tumours (a process called immuno-editing”
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790 · cited 1×
“This transcription factor is constitutively activated both in tumour cells and in immune cells, and is involved in oncogenesis and inhibition of apoptosi”
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695 · cited 1×
“TAMs have been described as “obligate partners for tumour-cell migration, invasion and metastasis&rdquo”
Cited by
Items 101–200 of 1,085
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
“TAM are M2-like polarized macrophages (Mantovani et al., 2008; Solinas et al., 2010) with lowexpression ofMHC IImolecules (MHC), although aproportion of M1-like MHC macrophages are present as well (Movahedi et al.”
BackgroundSelf-citationThe complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Nath, S., & Mukherjee, P. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.02.007 · Cited by 837
“These inflammatory mediators activate oncogenic pathways in tumor cells, stromal cells, and leukocytes that augment proliferation, resistance to apoptosis, invasion, angiogenesis, and suppress antitumor immune responses [78].”
BackgroundmiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101823 · Cited by 861
“cancer are intimately linked (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; Karin, 2006; Mantovani et al., 2008).”
BackgroundA guiding map for inflammation
Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3790 · Cited by 831
Self-citationTNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
Wu, Y., & Zhou, B. P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605530 · Cited by 798
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment
Kim, J., & Bae, J.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/6058147 · Cited by 802
Imaging macrophages with nanoparticles
Weissleder, R., Nahrendorf, M., & Pittet, M. J. (2014) · Nature Materials · doi:10.1038/nmat3780 · Cited by 809
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“The tumor-promoting effects of inflammatory cytokines are chiefly mediated by the activation of NF B and Stat3 signaling pathways and contribute to angiogenesis and changes to the cancer cells that allow them to change from an epithelial to a mesenchymal cell phenotype that has more metastatic properties (128).”
BackgroundQi, Q., Zhuang, L., Shen, Y., Geng, Y., Yu, S., Chen, H., Liu, L., Meng, Z., Wang, P., & Chen, Z. (2016) · Cancer · doi:10.1002/cncr.30057 · Cited by 761
“The hallmarks of cancer-related inflammation include the presence of inflammatory cells and inflammatory mediators (ie, chemokines, cytokines, etc) in tumor tissues.(23) A leukocyte infiltrate is present in most tumors.”
BackgroundIAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
“It is now recognized that chronic situations, in which unresolved inflammation causes tissue damage and triggers incessant tissue repair and remodelling, strongly contributes to a multitude of human diseases, including cance”
BackgroundThe head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 765
“shown to promote immune-mediated tumor clearance (38–41), effectors of innate immunity can lead to an inflammatory response and increase regional blood flow and angiogenesis, possibly contributing to tumor growth and progression (42).”
BackgroundThe Intestinal Microbiota in Colorectal Cancer.
Tilg, H., Adolph, T. E., Gerner, R. R., & Moschen, A. R. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.004 · Cited by 777
Gocheva, V., Wang, H.-W., Gadea, B. B., Shree, T., Hunter, K. E., Garfall, A. L., Berman, T., & Joyce, J. A. (2010) · Genes & Development · doi:10.1101/gad.1874010 · Cited by 740
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
Candido, J., & Hagemann, T. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9847-0 · Cited by 653
“IL-10 is an immunosuppressive and anti-inflammatory cytokine also linked with inflammation-associated cancer [7].”
Resolvin D1 binds human phagocytes with evidence for proresolving receptors
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.-H., Yang, R., Petasis, N. A., & Serhan, C. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907342107 · Cited by 730
“Excessive inflammation has emerged as a critical component in many prevalent human diseases such as atherosclerosis and cancer (2, 3).”
BackgroundRelationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer
Caliri, A. W., Tommasi, S., & Besaratinia, A. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108365 · Cited by 681
“Altogether, it is estimated that chronic inflammation contributes to 15–25% of human cancers [215,216].”
BackgroundYang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
“factors that are closely involved in tumor-associated inflammation (17,18).”
BackgroundThe Ins and Outs of the Epithelial to Mesenchymal Transition in Health and Disease
Nieto, M. A. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154036 · Cited by 720
“Transition, Inflammation, Hypoxia, and Immunity Inflammation has been linked to the progression of organ fibrosis and cancer for decades (reviewed in Cordon-Cardo & Prives 1999, Mantovani et al. 2008), but only recently have the molecular mechanisms begun to be elucidated.”
BackgroundWiig, H., & Swartz, M. A. (2012) · Physiological Reviews · doi:10.1152/physrev.00037.2011 · Cited by 722
“The composition and structure of the normal interstitium (50, 91, 147, 216, 246, 374) and that of tumors (93, 230, 231, 273, 282, 303, 444) have been covered in several extensive reviews and are thus only briefly described here.”
BackgroundTempleton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
“Inflammation is a hallmark of cancer (1) and there is often a complex host–tumor relationship with most tumors having inflammatory cells and mediators present in their microenvironment (2, 3).”
BackgroundDomingues, B., Lopes, J., Soares, P., & Populo, H. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134842 · Cited by 701
“TILs can mediate immune responses of the host against cancer cells, being associated with a positive outcome and improved survival in patients with malignant melanomas.(43,44) Based on these interactions, immunotherapy appears to be a promising treatment option for patients with advanced stage (metastatic) malignant m…”
BackgroundResultMetabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 721
The flavonoid quercetin in disease prevention and therapy: Facts and fancies
Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S., & Russo, G. L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.010 · Cited by 698
“These cytokines, which are mainly secreted by cytotoxic T cells or natural killer (NK) cells, are important in preventing the growth of tumors by the immune system, especially in the early stages, when these cells are involved in the recognition and subsequent elimination of transformed cells (immunosurveillance) [50].”
BackgroundDe Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
“ment, which may account for 15%–20% of cancer deaths (25), more recent efforts have been dedicated to understanding tumor-elicited inflammation, the inflammatory reaction that follows tumor development and is detected in nearly all solid malignancies.”
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 683
Origins of tumor-associated macrophages and neutrophils
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 689
“The latter cells are released into circulation and can extravasate in distant tissue (1, 14, 15).”
BackgroundMethodCancer-related inflammation: Common themes and therapeutic opportunities
Balkwill, F. R., & Mantovani, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.005 · Cited by 685
“prostatitis) [1].”
BackgroundInfluentialSelf-citationTlaskalová-Hogenová, H., Štěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., Rossmann, P., Hrnčíř, T., Kverka, M., Zákostelská, Z., et al. (2011) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.67 · Cited by 693
The two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
“To bypass impediments to T cell activation in situ in an immunuosuppressive cancer setting [1,3,4,6], the impact of IL-6-induced CD8+ T cell trafficking on tumors was examined using adoptive T cell transfer immunotherapy modeled after protocols currently in clinical use [17,84].”
BackgroundBremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
“In addition to tumor cells, pro-angiogenic factors are also secreted by pericytes [72], cancer-associated fibroblasts (CAF) [73], and cells of the immune system [74,75].”
BackgroundNusslock, R., & Miller, G. E. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.017 · Cited by 672
“These conditions range from traditional psychiatric disorders, like depression and substance misuse, to allergic, metabolic, cardiovascular, neoplastic, and rheumatic diseases (12,13,114,115).”
BackgroundInflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression
López‐Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 654
Mantovani, A. (2009) · Nature · doi:10.1038/457036b · Cited by 643
Self-citationThe Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010) · Nature · doi:10.1038/nature08782 · Cited by 639
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 617
“IL-1β generated in a tissue with a tumor microenvironment dominated by TAMs promotes tumor growth and metastasis in breast cancer [122, 125] .”
BackgroundZheng, P., Chen, L., Yuan, X., Luo, Q., Liu, Y., Xie, G., Ma, Y., & Shen, L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0528-y · Cited by 629
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 616
“2; Mantovani et al., 2008; Ruffell et al., 2012; Sica and Mantovani, 2012; Coussens et al., 2013; De Palma and Lewis, 2013; Colegio et al., 2014; Noy and Pollard, 2014).”
BackgroundInfluentialSelf-citationBreast cancer stem cells, cytokine networks, and the tumor microenvironment
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57099 · Cited by 616
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
“Further, in some cancer types, an inflammatory microenvironment restricts the immune system from rejecting malignant cells, and promotes the development of tumours [3].”
BackgroundTumor associated macrophages and neutrophils in cancer
Galdiero, M. R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., & Jaillon, S. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.06.003 · Cited by 597
Self-citationAnti-inflammatory activity of natural dietary flavonoids
Pan, M.-H., Lai, C.-S., & Ho, C.-T. (2010) · Food & Function · doi:10.1039/c0fo00103a · Cited by 605
Tumors: Wounds That Do Not Heal—Redux
Dvorak, H. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0209 · Cited by 592
Chronic Inflammation in Cancer Development
Multhoff, G., Molls, M., & Radons, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00098 · Cited by 576
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood
Weihrauch-Blüher, S., Schwarz, P., & Klusmann, J.-H. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.001 · Cited by 566
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“The intestine is a unique environment in host defense in which inflammation canplay a central role in resolving pathogenic infection, maintaining normal intestinal function, or promoting tumorigenesis (Balkwill and Mantovani 2001; Mantovani et al. 2008; Netea et al. 2017).”
BackgroundFcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.019 · Cited by 590
“…cells, macrophages, Tie2-expressing monocytes, neutrophils, DCs, IMCs, and CD4+ T cells, promote tumor development by activating angiogenic programs, suppressing antitumor immunity (Mantovani et al., 2008), and enhancing tumor cell migration and metastasis (DeNardo et al., 2009; Pollard, 2008).”
InfluentialChemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 583
“Inflammation is an essential component of the tumor microenvironment and one of the hallmarks of cancer (1, 2).”
BackgroundFazio, V., Robertis, M., Massi, E., Poeta, M., Carotti, S., Morini, S., Cecchetelli, L., & Signori, E. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.78279 · Cited by 579
“microenvironment) have been identified, both of which promote tumor growth.[107]”
BackgroundZhang, Y., Choksi, S., Chen, K., Pobezinskaya, Y., Linnoila, I., & Liu, Z.-G. (2013) · Cell Research · doi:10.1038/cr.2013.75 · Cited by 573
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
“In particular, antiangiogenic treatments and/or inhibitors of LGALS1-encoded protein (31) should be tested in mesenchymal colorectal cancer and the mesenchymal-like tumors.”
BackgroundInfluentialTargher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
HIF‐1 at the crossroads of hypoxia, inflammation, and cancer
Balamurugan, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.29519 · Cited by 572
Obstacles and opportunities for understanding macrophage polarization
Murray, P. J., & Wynn, T. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0710409 · Cited by 563
“The purpose of this short review is not to provide a comprehensive summary of macrophage subtypes or the CAM-AAM paradigm; this work has been reviewed by other researchers extensively [2–8].”
BackgroundMethodZhang, F., Wang, H., Wang, X., Jiang, G., Liu, H., Zhang, G., Wang, H., Fang, R., Bu, X., Cai, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10561 · Cited by 580
Choi, J., Park, J.-E., Tsagkogeorga, G., Yanagita, M., Koo, B.-K., Han, N., & Lee, J.-H. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.06.020 · Cited by 588
Exploring vitamin D metabolism and function in cancer
Jeon, S.-M., & Shin, E.-A. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0038-9 · Cited by 550
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
“Myeloid cells play a critical role in sustaining cancer progression (1).”
BackgroundHCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Single‐Layered Graphitic‐C3N4 Quantum Dots for Two‐Photon Fluorescence Imaging of Cellular Nucleus
Zhang, X., Wang, H., Wang, H., Zhang, Q., Xie, J., Tian, Y., Wang, J., & Xie, Y. (2014) · Advanced Materials · doi:10.1002/adma.201400111 · Cited by 560
Clinical significance of macrophage heterogeneity in human malignant tumors
Komohara, Y., Jinushi, M., & Takeya, M. (2014) · Cancer Science · doi:10.1111/cas.12314 · Cited by 551
The role of the complement system in cancer
Afshar-Kharghan, V. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90962 · Cited by 554
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
“A long-suspected causative connection between inflammation and cancer has been mechanistically established.”
BackgroundBauvois, B. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.001 · Cited by 543
“For example, gelatinases shed and activate TNF-α, TGF-β and IL-1β, which are intimately involved in the regulation of growth, angiogenesis and inflammation [56,57].”
BackgroundInflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments
Zuo, L., Prather, E. R., Stetskiv, M., Garrison, D. E., Meade, J. R., Peace, T. I., & Zhou, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184472 · Cited by 539
Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis
Kang, T., Zhu, Q., Wei, D., Feng, J., Yao, J., Jiang, T., Song, Q., Wei, X., Chen, H., Gao, X., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06477 · Cited by 551
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9223-6 · Cited by 515
“Immune-competent mouse models of human cancer have enabled a detailed evaluation of the tumor-promoting capacity of several subsets of myeloid cells, including mast cells (MCs), monocytes, granulocytes/neutrophils, and macrophages, as well as some subsets of lymphocytes [ 6 , 7]. However, depending on their differenti…”
BackgroundTumor-associated macrophages: Functional diversity, clinical significance, and open questions
Biswas, S. K., Allavena, P., & Mantovani, A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0367-7 · Cited by 551
Self-citationSignaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Comito, G., Giannoni, E., Segura, C. P., Barcellos-de-Souza, P., Raspollini, M. R., Baroni, G., Lanciotti, M., Serni, S., & Chiarugi, P. (2014) · Oncogene · doi:10.1038/onc.2013.191 · Cited by 528
Systemic inflammation markers and cancer incidence in the UK Biobank
Nøst, T. H., Alcala, K., Urbarova, I., Byrne, K. S., Guida, F., Sandanger, T. M., & Johansson, M. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00752-6 · Cited by 526
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 531
An evolutionary perspective on field cancerization
Curtius, K., Wright, N. A., & Graham, T. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.102 · Cited by 509
Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses
Veronese, N., Solmi, M., Caruso, M. G., Giannelli, G., Osella, A. R., Evangelou, E., Maggi, S., Fontana, L., Stubbs, B., & Tzoulaki, I. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqx082 · Cited by 536
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand-Rosenberg, S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 521
The renin–angiotensin system and cancer: old dog, new tricks
George, A. J., Thomas, W. G., & Hannan, R. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2945 · Cited by 525
“The molecular basis for cancer-related inflammation and its effect on malignancy and disease progression has been previously reviewe”
BackgroundInduction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 506
Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A., & Shahbazi, M. (2021) · Small · doi:10.1002/smll.202006484 · Cited by 528
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Pollier, J., & Goossens, A. (2012) · Phytochemistry · doi:10.1016/j.phytochem.2011.12.022 · Cited by 499
Role of the Tumor Microenvironment in Breast Cancer
Soysal, S. D., Tzankov, A., & Muenst, S. E. (2015) · Pathobiology · doi:10.1159/000430499 · Cited by 510
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
“For example, the continuous inflammatory responses to persistent infection with Helicobacter pylori or hepatitis viruses as well as chronic autoimmune reactions, such as those associated with inflammatory bowel disease, can pave the way for cancer development 63 .”
Dual-responsive biohybrid neutrobots for active target delivery
Zhang, H., Li, Z., Gao, C., Fan, X., Pang, Y., Li, T., Wu, Z., Xie, H., & He, Q. (2021) · Science Robotics · doi:10.1126/scirobotics.aaz9519 · Cited by 518
High-mobility group box 1 and cancer
Tang, D., Kang, R., Zeh III, H. J., & Lotze, M. T. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.014 · Cited by 512
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Properties and Therapeutic Application of Bromelain: A Review
Pavan, R., Jain, S., Shraddha, & Kumar, A. (2012) · Biotechnology Research International · doi:10.1155/2012/976203 · Cited by 484
Metadata
- Authors
- Mantovani, A., Allavena, P., Sica, A., & Balkwill, F.
- Affiliations
- IRCCS Humanitas Research Hospital (IT)
- Fondazione Humanitas per la Ricerca (IT)
- Queen Mary University of London (GB)
- Venue
- Nature
- Published
- 2008-07-01
- Volume
- 454
- Issue
- 7203
- Pages
- 436-444
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2123105952
- Semantic Scholar
- b3a9e344a32ad6ca402d9149ac74b2b1df9e3076
- Cited by
- 11,399
- References
- 175
- Citations by year
- 2026: 419 · 2025: 554 · 2024: 655 · 2023: 761 · 2022: 848 · 2021: 878 · 2020: 864 · 2019: 759 · 2018: 752 · 2017: 732 · 2016: 692 · 2015: 683 · 2014: 643 · 2013: 574 · 2012: 510
- FWCI
- 26.32
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- tumor inflammation, tumor microenvironment, inflammatory mediators, angiogenesis, metastasis, immune evasion, chemoresistance, endocrine response, inflammatory signaling, therapeutic target
- MeSH terms
- Humans, Inflammation, Leukocytes, Neoplasm Invasiveness, Neoplasms, Oncogenes, Gonadal Steroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.